- Home
- M vs PTGX Comparison
M vs PTGX Comparison
Compare M & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- M
- PTGX
- Stock Information
- Founded
- M 1830
- PTGX 2006
- Country
- M United States
- PTGX United States
- Employees
- M N/A
- PTGX N/A
- Industry
- M Department/Specialty Retail Stores
- PTGX Biotechnology: Pharmaceutical Preparations
- Sector
- M Consumer Discretionary
- PTGX Health Care
- Exchange
- M Nasdaq
- PTGX Nasdaq
- Market Cap
- M 3.3B
- PTGX 2.9B
- IPO Year
- M N/A
- PTGX 2016
- Fundamental
- Price
- M $11.05
- PTGX $53.34
- Analyst Decision
- M Hold
- PTGX Strong Buy
- Analyst Count
- M 10
- PTGX 9
- Target Price
- M $13.22
- PTGX $67.11
- AVG Volume (30 Days)
- M 7.8M
- PTGX 898.5K
- Earning Date
- M 05-28-2025
- PTGX 08-05-2025
- Dividend Yield
- M 6.61%
- PTGX N/A
- EPS Growth
- M N/A
- PTGX N/A
- EPS
- M 1.98
- PTGX 0.86
- Revenue
- M $22,799,000,000.00
- PTGX $207,801,000.00
- Revenue This Year
- M N/A
- PTGX N/A
- Revenue Next Year
- M N/A
- PTGX $47.15
- P/E Ratio
- M $5.57
- PTGX $62.27
- Revenue Growth
- M N/A
- PTGX N/A
- 52 Week Low
- M $9.76
- PTGX $30.67
- 52 Week High
- M $20.47
- PTGX $60.60
- Technical
- Relative Strength Index (RSI)
- M 40.90
- PTGX 58.33
- Support Level
- M $11.19
- PTGX $54.48
- Resistance Level
- M $11.89
- PTGX $57.18
- Average True Range (ATR)
- M 0.42
- PTGX 2.04
- MACD
- M -0.10
- PTGX -0.09
- Stochastic Oscillator
- M 3.68
- PTGX 57.13
About M Macy's Inc
Founded in 1858 and based in New York City, Macy's operates about 450 stores under the Macy's nameplate, nearly 60 stores under the Bloomingdale's (full-price and outlet) and Bloomie's nameplates, and more than 170 freestanding Bluemercury specialty beauty stores. Macy's also operates e-commerce sites and licenses Bloomingdale's stores in the United Arab Emirates and Kuwait. Women's apparel, accessories, shoes, cosmetics, and fragrances constitute about 62% of Macy's sales.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.